Changes in the incidence of periodontal pathogens during long-term monitoring and after application of antibacterial drugs
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Anti-Bacterial Agents therapeutic use MeSH
- Time Factors MeSH
- Adult MeSH
- Gram-Negative Bacterial Infections diagnosis drug therapy epidemiology microbiology MeSH
- Gram-Negative Bacteria drug effects isolation & purification MeSH
- Incidence MeSH
- Middle Aged MeSH
- Humans MeSH
- Drug Monitoring * MeSH
- Periodontal Diseases diagnosis drug therapy epidemiology microbiology MeSH
- Case-Control Studies MeSH
- Mouth microbiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
The incidence of potential periodontal pathogens (Aggregatibacter actinomycetemcomitans, formerly Actinobacillus actinomycetemcomitans, Tannerella forsythia, Porphyromonas gingivalis, Prevotella nigrescens, Prevotella intermedia and Capnocytophaga ochracea) was monitored in patients with chronic periodontitis and in healthy control subjects. Two types of studies were carried out in which the composition of the bacterial communities in different niches of the same oral cavity ecosystem was investigated. Fluctuation or at least pronounced quantitative changes in the incidence of individual species in time were documented in the long-term study as well as after the local administration of antibacterial drug Chlo-Site or Metronidazole. Even within two weeks, a turnover of the monitored bacteria in separate niches of the oral biotope can be detected. A relatively high incidence of the tested periopathogens in the clinically healthy teeth of patients implies that even the "healthy" niches in the periodontal biotope function as a dynamic reservoir of periopathogenic microorganisms. This should be kept in mind when a local application of antibacterial compounds is used in the therapy of periodontal disease.
See more in PubMed
Periodontol 2000. 2004;36:14-26 PubMed
Microbiol Mol Biol Rev. 2007 Dec;71(4):653-70 PubMed
Antimicrob Agents Chemother. 2006 Nov;50(11):3651-7 PubMed
J Clin Periodontol. 2001 Jul;28(7):697-700 PubMed
Eur J Oral Sci. 2006 Feb;114(1):58-63 PubMed
J Clin Periodontol. 2002 Nov;29(11):1023-8 PubMed
Infect Immun. 1994 May;62(5):1889-95 PubMed
J Oral Maxillofac Surg. 2006 Aug;64(8):1303-9 PubMed
Periodontol 2000. 1993 Jun;2:57-71 PubMed
J Clin Periodontol. 2004 Dec;31(12):1034-47 PubMed
Periodontol 2000. 1994 Jun;5:78-111 PubMed
J Clin Microbiol. 1999 Nov;37(11):3504-8 PubMed
Oral Microbiol Immunol. 1996 Aug;11(4):266-73 PubMed
Arch Oral Biol. 2004 Apr;49(4):295-304 PubMed
Nucleic Acids Res. 2002 Aug 1;30(15):3481-9 PubMed
Ann Periodontol. 1996 Nov;1(1):216-22 PubMed
FEMS Microbiol Lett. 2007 Jun;271(1):90-7 PubMed
